Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTAI BioXcel Therapeutics	$2.00 +0.3%	$1.64	$1.17 ▼ $21.92	$12.08M	0.04	1.22 million shs	300,875 shs
MGNX MacroGenics	$1.58 -0.6%	$1.48	$0.99 ▼ $5.77	$100.31M	1.59	847,700 shs	1.16 million shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs
URGN Urogen Pharma	$14.64 +6.0%	$9.88	$3.42 ▼ $18.15	$636.74M	1.02	1.09 million shs	1.46 million shs
VNDA Vanda Pharmaceuticals	$4.99 -0.6%	$4.48	$3.81 ▼ $6.37	$295.85M	0.68	603,946 shs	507,094 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTAI BioXcel Therapeutics	0.00%	+2.04%	+0.50%	+10.50%	-88.64%
MGNX MacroGenics	-0.63%	+9.72%	-11.24%	+22.48%	-63.00%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%
URGN Urogen Pharma	+6.01%	+8.52%	+107.66%	+44.66%	-10.68%
VNDA Vanda Pharmaceuticals	-0.60%	-0.08%	+7.08%	+20.82%	-4.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTAI BioXcel Therapeutics	4.4735 of 5 stars	3.3	4.0	0.0	4.5	3.0	1.7	0.6
MGNX MacroGenics	4.1396 of 5 stars	3.2	3.0	0.0	4.4	1.3	2.5	0.6
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	4.5504 of 5 stars	4.5	2.0	0.0	4.5	2.5	2.5	0.0
VNDA Vanda Pharmaceuticals	4.3861 of 5 stars	3.8	2.0	0.0	4.2	0.6	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	2,030.00% Upside
MGNX MacroGenics	2.40	Hold	$5.71	261.66% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A
URGN Urogen Pharma	3.00	Buy	$32.86	124.43% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	230.66% Upside

Current Analyst Ratings Breakdown

Latest VNDA, URGN, PRVB, MGNX, and BTAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTAI BioXcel Therapeutics	$2.27M	5.34	N/A	N/A	($30.01) per share	-0.07
MGNX MacroGenics	$152.43M	0.65	N/A	N/A	$1.85 per share	0.85
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
URGN Urogen Pharma	$90.40M	7.47	N/A	N/A	($0.21) per share	-69.71
VNDA Vanda Pharmaceuticals	$201.35M	1.46	N/A	N/A	$9.24 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTAI BioXcel Therapeutics	-$59.60M	-$13.55	N/A	N/A	N/A	-2,163.18%	N/A	-83.80%	8/5/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-21.98%	-8.30%	-6.85%	7/30/2025 (Estimated)

Latest VNDA, URGN, PRVB, MGNX, and BTAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	N/A	N/A	N/A	$0.21 million	N/A
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
7/30/2025	Q2 2025	VNDA Vanda Pharmaceuticals	-$0.34	N/A	N/A	N/A	$54.77 million	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTAI BioXcel Therapeutics	N/A	1.48	1.45
MGNX MacroGenics	N/A	3.28	3.11
PRVB Provention Bio	0.19	1.93	1.92
URGN Urogen Pharma	N/A	5.65	5.47
VNDA Vanda Pharmaceuticals	N/A	3.93	3.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTAI BioXcel Therapeutics	30.68%
MGNX MacroGenics	96.89%
PRVB Provention Bio	37.39%
URGN Urogen Pharma	91.29%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
BTAI BioXcel Therapeutics	21.20%
MGNX MacroGenics	13.00%
PRVB Provention Bio	13.10%
URGN Urogen Pharma	5.10%
VNDA Vanda Pharmaceuticals	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.04 million	Optionable

VNDA, URGN, PRVB, MGNX, and BTAI Headlines

Recent News About These Companies

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

July 10 at 4:21 AM | marketbeat.com

VNDA - Vanda Pharmaceuticals Inc Executives - Morningstar

July 9 at 11:07 PM | morningstar.comM

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Crosses Above 200-Day Moving Average - Should You Sell?

July 2, 2025 | marketbeat.com

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar

June 24, 2025 | morningstar.comM

Risks of a blockade in the Strait of Hormuz 'remain absolutely minimalistic': Vanda Insights

June 23, 2025 | youtube.comY

Insider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells 7,000 Shares of Stock

June 18, 2025 | insidertrades.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells $32,130.00 in Stock

June 17, 2025 | marketbeat.com

Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)

June 16, 2025 | gurufocus.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Hold at Wall Street Zen

June 14, 2025 | marketbeat.com

Brokers Issue Forecasts for VNDA FY2026 Earnings

June 11, 2025 | marketbeat.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

June 10, 2025 | finanznachrichten.de

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

June 10, 2025 | prnewswire.com

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 27, 2025 | prnewswire.com

Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Acquires 10,000 Shares of Stock

May 22, 2025 | insidertrades.com

Insider Buying: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Purchases 20,000 Shares of Stock

May 20, 2025 | insidertrades.com

Insider Buying: Mihael Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc (VNDA)

May 20, 2025 | gurufocus.com

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit ...

May 16, 2025 | gurufocus.com

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 16, 2025 | prnewswire.com

Vanda Pharmaceuticals (VNDA) Receives Overweight Rating from Cantor Fitzgerald | VNDA Stock News

May 14, 2025 | gurufocus.com

Vanda Pharmaceuticals (VNDA) Projected to Transform with Overweight Rating | VNDA Stock News

May 14, 2025 | gurufocus.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, URGN, PRVB, MGNX, and BTAI Company Descriptions

BioXcel Therapeutics NASDAQ:BTAI

$2.00 +0.01 (+0.25%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 08:15 AM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

MacroGenics NASDAQ:MGNX

$1.58 -0.01 (-0.63%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 07:48 AM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Urogen Pharma NASDAQ:URGN

$14.64 +0.83 (+6.01%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$14.46 -0.18 (-1.23%)

As of 09:08 AM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.99 -0.03 (-0.60%)

Closing price 07/10/2025 04:00 PM Eastern

Extended Trading

$5.02 +0.03 (+0.58%)

As of 07/10/2025 08:00 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time